Asymmetric dimethylarginine in hematological malignancies: a preliminary study

References

• McBride A E, Silver P A. State of the arg: protein methylation at arginine comes of age. Cell 2001; 106: 5–8
   PubMed Web of Science ®Google Scholar
• Vallance P, Leone A, Calver A, Collier J, Moncada S. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol 1992; 20(Suppl 12)S60–S62
   PubMed Web of Science ®Google Scholar
• Mehta S, Stewart D J, Langleben D, Levy R D. Short-term pulmonary vasodilation with L-arginine in pulmonary hypertension. Circulation 1995; 92: 1539–1545
   PubMed Web of Science ®Google Scholar
• Closs E I, Basha F Z, Habermeier A, Forstermann U. Interference of l-arginine analogues with L-arginine transport mediated by the y+ carrier hCAT-2B. Nitric Oxide 1997; 1: 65–73
   PubMed Web of Science ®Google Scholar
• Ignarro L J, Cirino G, Casini A, Napoli C. Nitric oxide as a signaling molecule in the vascular system: an overview. J Cardiovasc Pharmacol 1999; 34: 879–886
   PubMed Web of Science ®Google Scholar
• Cooke J P, Losordo D W. Nitric oxide and angiogenesis. Circulation 2002; 105: 2133–2135
   PubMed Web of Science ®Google Scholar
• Boger R H. Live and let die: asymmetric dimethylarginine and septic shock. Crit Care 2006; 10: 169
   PubMed Web of Science ®Google Scholar
• Cauwels A. Nitric oxide in shock. Kidney Int 2007; 72: 557–565
   PubMed Web of Science ®Google Scholar
• Lind D S. Arginine and cancer. J Nutr 2004; 134: 2837S–2841S, discussion 2853S
   PubMed Web of Science ®Google Scholar
• Billard C, Quiney C, Tang R, Kern C, Ajchenbaum-Cymbalista F, Dauzonne D, et al. The inducible NO synthase is downregulated during apoptosis of malignant cells from B-cell chronic lymphocytic leukemia induced by flavopiridol and polyphenols. Ann N Y Acad Sci 2003; 1010: 381–383
   PubMed Web of Science ®Google Scholar
• Boger R H, Zoccali C. ADMA: a novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease. Atheroscler Suppl 2003; 4: 23–28
   PubMed Web of Science ®Google Scholar
• Kimoto M, Whitley G S, Tsuji H, Ogawa T. Detection of NG,NG-dimethylarginine dimethylaminohydrolase in human tissues using a monoclonal antibody. J Biochem (Tokyo) 1995; 117: 237–238
   PubMed Web of Science ®Google Scholar
• Wang J, Sim A S, Wang X L, Wilcken D E. L-arginine regulates asymmetric dimethylarginine metabolism by inhibiting dimethylarginine dimethylaminohydrolase activity in hepatic (HepG2) cells. Cell Mol Life Sci 2006; 63: 2838–2846
   PubMed Web of Science ®Google Scholar
• Miyazaki H, Matsuoka H, Cooke J P, Usui M, Ueda S, Okuda S, et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999; 99: 1141–1146
   PubMed Web of Science ®Google Scholar
• Anthony S, Leiper J, Vallance P. Endogenous production of nitric oxide synthase inhibitors. Vasc Med 2005; 10(Suppl 1)S3–S9
   PubMed Web of Science ®Google Scholar
• Valkonen V P, Paiva H, Salonen J T, Lakka T A, Lehtimaki T, Laakso J, et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001; 358: 2127–2128
   PubMed Web of Science ®Google Scholar
• Boger R H. Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials. Vasc Med 2005; 10(Suppl 1)S19–S25
   PubMed Web of Science ®Google Scholar
• Zoccali C, Bode-Boger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001; 358: 2113–2117
   PubMed Web of Science ®Google Scholar
• Schnabel R, Blankenberg S, Lubos E, Lackner K J, Rupprecht H J, Espinola-Klein C, et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res 2005; 97: e53–e59
   PubMed Web of Science ®Google Scholar
• Mittermayer F, Krzyzanowska K, Exner M, Mlekusch W, Amighi J, Sabeti S, et al. Asymmetric dimethylarginine predicts major adverse cardiovascular events in patients with advanced peripheral artery disease. Arterioscler Thromb Vasc Biol 2006; 26: 2536–2540
   PubMed Web of Science ®Google Scholar
• Krzyzanowska K, Mittermayer F, Wolzt M, Schernthaner G. Asymmetric dimethylarginine predicts cardiovascular events in patients with type 2 diabetes. Diabetes Care 2007; 30: 1834–1839
   PubMed Web of Science ®Google Scholar
• Nijveldt R J, Siroen M P, Teerlink T, van Leeuwen P A. Elimination of asymmetric dimethylarginine by the kidney and the liver: a link to the development of multiple organ failure?. J Nutr 2004; 134: 2848S–2852S, discussion 2853S
   PubMed Web of Science ®Google Scholar
• Boger R H. Association of asymmetric dimethylarginine and endothelial dysfunction. Clin Chem Lab Med 2003; 41: 1467–1472
   PubMed Web of Science ®Google Scholar
• Boger R H, Bode-Boger S M, Szuba A, Tsao P S, Chan J R, Tangphao O, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998; 98: 1842–1847
   PubMed Web of Science ®Google Scholar
• Cockcroft D W, Gault M H. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31–41
   PubMed Web of Science ®Google Scholar
• Boisvert F M, Cote J, Boulanger M C, Richard S. A proteomic analysis of arginine-methylated protein complexes. Mol Cell Proteomics 2003; 2: 1319–1330
   PubMed Web of Science ®Google Scholar
• Wu G, Morris S M, Jr. Arginine metabolism: nitric oxide and beyond. Biochem J 1998; 336(Pt 1)1–17
   PubMed Web of Science ®Google Scholar
• Wu G, Meininger C J, Knabe D A, Bazer F W, Rhoads J M. Arginine nutrition in development, health and disease. Curr Opin Clin Nutr Metab Care 2000; 3: 59–66
   PubMedGoogle Scholar
• Murray-Rust J, Leiper J, McAlister M, Phelan J, Tilley S, Santa Maria J, et al. Structural insights into the hydrolysis of cellular nitric oxide synthase inhibitors by dimethylarginine dimethylaminohydrolase. Nat Struct Biol 2001; 8: 679–683
   PubMedGoogle Scholar
• Ito A, Tsao P S, Adimoolam S, Kimoto M, Ogawa T, Cooke J P. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999; 99: 3092–3095
   PubMed Web of Science ®Google Scholar
• Giles G I. The redox regulation of thiol dependent signaling pathways in cancer. Curr Pharm Des 2006; 12: 4427–4443
   PubMed Web of Science ®Google Scholar
• Sydow K, Munzel T. ADMA and oxidative stress. Atheroscler Suppl 2003; 4: 41–51
   PubMed Web of Science ®Google Scholar
• Konukoglu D, Firtina S, Serin O. The relationship between plasma asymmetrical dimethyl-L-arginine and inflammation and adhesion molecule levels in subjects with normal, impaired, and diabetic glucose tolerance. Metabolism 2008; 57: 110–115
   PubMed Web of Science ®Google Scholar
• Zoccali C, Benedetto F A, Maas R, Mallamaci F, Tripepi G, Malatino L S, et al. Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J Am Soc Nephrol 2002; 13: 490–496
   PubMed Web of Science ®Google Scholar
• Oeffinger K C. Are survivors of acute lymphoblastic leukemia (ALL) at increased risk of cardiovascular disease?. Pediatr Blood Cancer 2008; 50: 462–467, discussion 468
   PubMed Web of Science ®Google Scholar
• Dengel D R, Ness K K, Glasser S P, Williamson E B, Baker K S, Gurney J G. Endothelial function in young adult survivors of childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2008; 30: 20–25
   PubMed Web of Science ®Google Scholar
• Abbasi F, Asagmi T, Cooke J P, Lamendola C, McLaughlin T, Reaven G M, et al. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 2001; 88: 1201–1203
   PubMed Web of Science ®Google Scholar
• Stuhlinger M C, Stanger O. Asymmetric dimethyl-L-arginine (ADMA): a possible link between homocyst(e)ine and endothelial dysfunction. Curr Drug Metab 2005; 6: 3–14
   PubMed Web of Science ®Google Scholar
• Perticone F, Sciacqua A, Maio R, Perticone M, Maas R, Boger R H, et al. Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension. J Am Coll Cardiol 2005; 46: 518–523
   PubMed Web of Science ®Google Scholar
• Nijveldt R J, Teerlink T, van Leeuwen P A. The asymmetrical dimethylarginine (ADMA)-multiple organ failure hypothesis. Clin Nutr 2003; 22: 99–104
   PubMed Web of Science ®Google Scholar
• Cooke J P. Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of angiogenesis. Eur J Clin Pharmacol 2006; 62(Suppl 1)115–121
   Web of Science ®Google Scholar
• Grabon W. [Arginine as a crucial amino acid in carcinogenesis and tumor growth]. Postepy Hig Med Dosw (Online) 2006; 60: 483–489
   PubMedGoogle Scholar